Nombre del producto:4-Bromo-2-fluorotoluene

IUPAC Name:4-bromo-2-fluoro-1-methylbenzene

CAS:51436-99-8
Fórmula molecular:C7H6BrF
Pureza:95%+
Número de catálogo:CM253316
Peso molecular:189.03

Unidad de embalaje Stock disponible Precio($) Cantidad
CM253316-1000g in stock ƿŹȃ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :51436-99-8
Fórmula molecular:C7H6BrF
Punto de fusión:-
Código de sonrisas:C1=C(C(=CC=C1Br)C)F
Densidad:
Número de catálogo:CM253316
Peso molecular:189.03
Punto de ebullición:183.2°C at 760 mmHg
Nº Mdl:MFCD00013551
Almacenamiento:Store at room temperature.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Crinecerfont
The New England Journal of Medicine publishes the primary CAHtalyst™ Adult Phase 3 study results of Crinecerfont for the treatment of congenital adrenal hyperplasia (CAH). Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare genetic disorder, affected by a lack of cortisol and/or aldosterone. Corticotropin-releasing factor type 1 receptor (CRF1) antagonism is shown to clinically decrease ACTH production and adrenal androgen levels.
Neurocrine's Crinecerfont is an investigational, selective CRF1 antagonist being developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens. The phase 3 study meets primary and important key secondary endpoints, including a significant reduction in androstenedione levels and lowering glucocorticoid dosing.